Brief: Advaxis Announces Positive Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial

Ayala Pharmaceuticals

20/02/2020 13:45

Feb 20 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS ANNOUNCES POSITIVE CLINICAL DATA IN ONGOING PHASE
1/2
ADXS-503 TRIAL IN NSCLC AT THE IASLC 2020 TARGETED THERAPIES OF
LUNG CANCER MEETING
    * ADVAXIS - ADXS-503 SAFE, TOLERABLE WITH POTENTIAL SIGNS OF
CLINICAL ACTIVITY IN 4/7 EVALUABLE PATIENTS ACHIEVING STABLE
DISEASE IN REFRACTORY SETTING
    * ADVAXIS - PATIENT WHO PREVIOUSLY PROGRESSED ON
PEMBROLIZUMAB
SHOWED STABLE DISEASE WITH A 25% REDUCTION IN A SITE LESION IN
COMBINATION ARM

Source text for Eikon:  ID:nGNXbjvX1g 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))